Waldemar F Pfrengle

USPTO Granted Patents = 40 (Patent Applications = 4)

CIPO Patents = 5

EPO Patents = 15 (Patent Applications = 9)

Average Co-Inventor Count = 2.1

ph-index = 12

Forward Citations = 492(Granted Patents)

Location History:

Seibersbach, DE (1995 - 2008)
Siebersbach, DE (2008)
Ingelheim am Rhein, DE (2012)
Biberach, DE (2005 - 2014)
Biberach an de Riss, DE (2014)
Biberach an der Riss, DE (2014 - 2017)

Company Filing History:

18 out of 1,537

Boehringer Ingelheim International Gmbh

patents

12 out of 3,580

American Cyanamid Company

patents

6 out of 10,754

Basf Aktiengesellschaft

patents

4. 3 out of 101

Shell Research Limited

Years Active: 1995-2017

Loading Chart...

Areas of Expertise:

Chiral Xanthines

Quinazolines

Pharmaceutical Compositions

Bicyclic Heterocycles

Anticancer Agents

Fungicidal Compounds

Triazolopyrimidines

Spirocyclic Amines

Anticholinergic Efficacy

Stereoselective Preparation

Tiotropium Salts

Xanthine Compounds

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9751855 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2017-09-05),

2. 9499546 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2016-11-22),

3. 9212183 - Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (2015-12-15),

4. 9199998 - Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions (2015-12-01),

5. 8962636 - Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions (2015-02-24),

6. 8906931 - 9-[4-(3-chloro-2-fluoro-phenylamino-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof (2014-12-09),

7. 8883805 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2014-11-11),

8. 8883800 - Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions (2014-11-11),

9. 8865729 - Salt forms of a xanthine compound (2014-10-21),

10. 8686148 - Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof (2014-04-01),

11. 8637530 - 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals (2014-01-28),

12. 8541450 - Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines (2013-09-24),

13. 8263768 - Process for the stereoselective preparation of bicyclic heterocycles (2012-09-11),

14. 8207335 - Process for making certain compounds having B1 antagonistic activity (2012-06-26),

15. 8106060 - 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals (2012-01-31),

Title: Waldemar F. Pfrengle: Innovator in Chiral Chemistry

Introduction

Waldemar F. Pfrengle, a prominent inventor based in Seibersbach, Germany, has made substantial contributions to the field of chemistry with a remarkable portfolio of 40 patents. His pioneering work focuses primarily on the synthesis of chiral compounds, which are crucial for the development of pharmaceuticals.

Latest Patents

Among his latest innovations is the patent titled "Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines." This invention details an improved method for producing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines, which are valuable in medicinal chemistry. The significance of this work lies in its potential applications in creating more effective drugs with fewer side effects.

Career Highlights

Waldemar’s professional journey includes significant roles in well-known companies such as Boehringer Ingelheim International GmbH and American Cyanamid Company. His experiences in these organizations have undoubtedly shaped his innovative approaches to chemical synthesis and patent development.

Collaborations

Throughout his career, Waldemar has collaborated with esteemed colleagues, including Klaus-Juergen Pees and Guido Albert. These partnerships have fostered an environment of creativity and innovation, enabling advancements in their respective fields.

Conclusion

Waldemar F. Pfrengle exemplifies the spirit of innovation within the realm of chemistry. His extensive patent collection not only showcases his expertise but also underscores his commitment to advancing pharmaceutical science through the development of chiral compounds. As he continues to push the boundaries of research and invention, his contributions will undoubtedly leave a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.